The use of statin drugs in patients with chronic kidney disease, combined with dyslipidemia

D.D. Ivanov, Ya.A. Dombrovskyi


For medical treatment to reduce cholesterol levels by most international cardiology and nephrology associations recommended prescriptions of statin as monotherapy or combination with other drugs. The tоpic of this article is devoted to the comparative characteristic of this group of drugs for use in patients with chronic kidney disease associated with dyslipidemia. The main part of the article is an analysis of pharmacodynamics, efficacy, safety and expediency of using rosuvastatin, a drug from the group of the last generation of statins.


chronic kidney disease; dyslipidemia; statins; rosuvastatin


KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease (Summary of Recommendation Statements), 2013.

Справочник ВИДАЛЬ. — 2006.

Schuster H. et al. Effects of switching statins on achievement of lipid goals. — Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study // Am. Heart J. — 2004. — 147. — 705-12.

Betteridge D.J., Gibson M. Effect of rosuvastatin on LDL-C and CRP levels in patients with type 2 diabetes: results of ANDROMEDA study // Atheroscler. Suppl. — 2004. — 5. — 107-108.

Ridker P.M., Cannon C.P. et al. for PROVE IT-TIMI 22 Investigators. C-reactive protein levels and outcomes after statin therapy // N. Engl. J. Med. — 2005. — Vol. 352, № 1. — 20-28.

Wahre T., Yundestat A., Smith C. et al. Increased Expression of Interleukin-1 in Coronary Artery Disease With Downregulatory Effects of HMG-CoA Reductase Inhibitors // Circulation. — 2004. — Vol. 109, № 16. — 1966-1972.

Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway // Nature. — 1990. — 343. — 425-430.

Jones P.H., Davidson M.H., Stein E.A. et al. for the STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial) // Am. J. Cardiol. — 2003. — 92. — 152-160.

Nissen S. et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis // The ASTEROID JAMA. — 2006. — 295 (13). — 1556-1565.

Nade V.S., Kawale L.A., Patel K.M. Protective effect of sitagliptin and rosuvastatin combination on vascular endothelial dysfunction in type-2diabetes // Indian J. Pharm. Sci. — 2015 Jan-Feb. — 77 (1). — 96-102.

Zhang J., Li Y., Tao G.Z., Chen Y.D., Hu T.H., Cao X.B., Jing Q.M., Wang X.Z., Ma Y.Y., Wang G., Liu H.W., Wang B., Xu K., Li J., Deng J., Han Y.L. Short-term Rosuvastatin Treatment for the Prevention of Contrast-induced Acute Kidney Injury in Patients Receiving Moderate or High Volumes of Contrast Media: A Sub-ana­lysis of the TRACK-D Study // Chin. Med. J. (Engl). — 2015 20th Mar. — 128 (6). — 784-789.

Halcox J.P., Tubach F., Lopez-Garcia E., De Backer G., Borghi C., Dallongeville J., Guallar E., Medina J., Perk J., Sazova O., Sweet S., Roy C., Banegas J.R., Rodriguez-Artalejo F. Low rates of both lipid-lowering therapy use and achievement of low-density lipoprotein cholesterol targets in individuals at high-risk for cardiovascular disease across Europe // PLoS One. — 2015 Feb 18. — 10 (2). — e0115270.

Pitt B., Ellis S.G., Mancini G.B.J. et al. (b) Pitt B., Mancini G.B.J., Ellis S.G. et al. (a) Design and recruitment in the United States of a multicenter quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC I) (b) Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I). — reduction in atherosclerosis progression and clinical events // (a) Am. J. Cardiol. — 1993. — 72. — 31-5; (b) J. Am. Coll. Cardiol. — 1995. — 26. — 1133-9.

Blankenhorn D.H., Azen S.P., Kramsch D.M. et al. (b) Alaupovic P., Hodis H.N., Knight-Gibson C. et al. (c) Mack W.J., Krauss R.M., Hodis H.N. (a) Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS) (b) Effects of lovastatin on apoA- and apoB-containing lipoproteins. Families in a subpopulation of patients participating in the Monitored Atherosclerosis Regression Study (MARS) (c) Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression // (a) Ann. Intern. Med. — 1993. — 119. — 969-76; (b) Arterioscler. Thromb. — 1994. — 14. — 1906-14; (c) Arterioscler. Thromb. Vasc. Biol. — 1996. — 16. — 697-704.

MAAS investigators Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS) Reference(s) // Lancet. — 1994. — 344. — 633-8.

Waters D., Higginson L., Gladstone P. et al. (b) Waters D., Higginson L., Gladstone P. et al. (a) Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial (b) Effects of cholesterol lowering on the progression of coronary atherosclerosis in women: a Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) substudy // (a) Circulation. — 1994. — 89. — 959-68; (b) Circulation. — 1995. — 92. — 2404-10.

Kinlay S., Schwartz G.G., Olsson et al. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in Myocardial Ischemia Reduction and Aggressive Cholesterol Lowering (MIRACL) Study // Circulation. — 2004. — Vol. 110. — 386-391.

Gibbons G.H. Cardioprotective mechanisms of ACE inhibition. The angiotensin II nitric oxide balance // Drugs. — 1997. — 54 (suppl. 5). — 1-11.

Worthylake R.A., Lemoine S., Watson J.M., Burridge K. RhoA is required for monocyte tail retraction during transendothelial migration // J. Cell. Biol. — 2001. — 154. — 147-160.

Amano M., Fukata Y., Kaibuchi K. Regulation and functions of Rho-associated kinase // Exp. Cell. Res. — 2000. — 261. — 44-51.

Tamai O., Matsuoka H., Itabe H. et al. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans // Circulation. — 1997. — 95. — 76-82.

Taddei S., Virdis A., Mattei P. et al. Endothelium-dependent forearm vasodilation is reduced in normotensive subjects with familial history of hypertension // J. Cardiovasc. Pharmacol. — 1992. — 20 (suppl. 12). — S193-S195.

Treasure C.B., Klein J.L., Weintraub W.S. et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease // N. Engl. J. Med. — 1995. — 332. — 481-487.

Increased Frequency of Microalbuminuria in Patients Receiving Statins / Nicolas Roberto Robles, Joaquin Velasco, Candido Mena, Jose Polo, Enrique Angulo, Jacinto Espinosa // Clin. Lipido­logy. — 2013. — 8 (2). — 257-262.

Navarese E.P., Buffon A., Andreotti F. et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus // Am. J. Cardiol. — 2013 Apr 15. — 111 (8). — 1123-30. doi: 10.1016/j.amjcard.2012.12.037. Epub 2013 Jan 24. (Review) PMID: 23352266

Abaci O., Ozkan A.A., Kocas C. et al. Impact of Rosuvastatin on Contrast-Induced Acute Kidney Injury in Patients at High Risk for Nephropathy Undergoing Elective Angiography // Am. J. Cardiol. — 2015 Jan 14. pii: S0002-9149(15)00042-9. doi: 10.1016/j.amjcard.2015.01.007. (Original) PMID: 25670636

Meta-analysis of short-term high versus low doses of atorva­statin preventing contrast-induced acute kidney injury in patients undergoing coronary angiography/percutaneous coronary intervention // J. Clin. Pharmacol. — 2015 Feb. — 55 (2). — 123-31. doi: 10.1002/jcph.411. Epub 2015 Jan 5. (Review) PMID: 25310898

American Diabetes Association. Standards of Medical Care in Diabetes — 2015 // Diabetes Care. DOI: 10.2337/dc15-S005

Copyright (c) 2020 D.D. Ivanov, Ya.A. Dombrovskyi

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© "Publishing House "Zaslavsky", 1997-2020


   Seo анализ сайта